长春高新：金赛药业GS3-007a干混悬剂境内生产药品注册临床试验申请获得受理

Group 1 - The core point of the article is that Changchun High-tech (000661) announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd., received the acceptance notice from the National Medical Products Administration for the clinical trial application of GS3-007a suspension [1] - GS3-007a is an orally administered small molecule growth hormone secretagogue developed by Jinsai Pharmaceutical, classified as a Class 1 chemical drug [1] - The drug is intended for the treatment of pediatric growth hormone deficiency (PGHD) caused by endogenous growth hormone deficiency [1]